1. Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors
- Author
-
Luigiana Luciano, Giorgina Specchia, Elisabetta Abruzzese, Nicola Sgherza, Francesco Albano, Fabio Stagno, Patrizia Pregno, Francesco Cavazzini, Antonella Russo Rossi, Gianantonio Rosti, Massimo Breccia, Giuseppe Visani, Mario Annunziata, Mario Tiribelli, Antonella Gozzini, Fausto Castagnetti, Carmen Fava, Bruno Martino, Giuliana Alimena, Pellegrino Musto, Russo Rossi AV., Breccia M., Abruzzese E., Castagnetti F., Luciano L., Gozzini A., Annunziata M., Martino B., Stagno F., Cavazzini F., Tiribelli M., Visani G., Pregno P., Musto P., Fava C., Sgherza N., Albano F., Rosti G., Alimena G., and Specchia G.
- Subjects
Oncology ,Male ,NILOTINIB ,Dasatinib ,Pharmacology ,THERAPY ,Tyrosine-kinase inhibitor ,Cytogenetic Response ,hemic and lymphatic diseases ,80 and over ,Treatment Failure ,Chronic ,IMATINIB-RESISTANT ,BCR-ABL ,Aged, 80 and over ,Leukemia ,CHRONIC MYELOGENOUS LEUKEMIA ,Myeloid leukemia ,Hematology ,Articles ,Middle Aged ,Treatment Outcome ,Female ,Tyrosine kinase ,medicine.drug ,third line treatment ,Adult ,medicine.medical_specialty ,medicine.drug_class ,Last follow up ,MESYLATE ,NO ,Internal medicine ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,medicine ,Humans ,2ND ,Protein Kinase Inhibitors ,CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL, IMATINIB-RESISTANT, DOMAIN MUTATIONS, MESYLATE, RESPONSES, EFFICACY, THERAPY, 2ND ,Aged ,business.industry ,Disease progression ,DOMAIN MUTATIONS ,EFFICACY ,Pyrimidines ,Thiazoles ,Nilotinib ,BCR-ABL Positive ,business ,CHRONIC MYELOID LEUKEMIA (CML) ,RESPONSES ,Myelogenous - Abstract
There have been few reports of a response to dasatinib or nilotinib after failure of two prior sequential tyrosine kinase inhibitors. We report the outcome of 82 chronic phase patients who received nilotinib or dasatinib as third-line alternative tyrosine kinase inhibitor therapy. Thirty-four patients failed to respond to nilotinib and were started on dasatinib as third-line tyrosine kinase inhibitor therapy while 48 patients were switched to nilotinib after dasatinib failure. Overall, we obtained a cytogenetic response in 32 of 82 patients and major molecular response in 13 patients; disease progression occurred in 12 patients. At last follow up, 70 patients (85.4%) were alive with a median overall survival of 46 months. Our results show that third-line tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients after failure of two prior sequential tyrosine kinase inhibitors may induce a response that, in some instances, could prolong overall survival and affect event-free survival.
- Published
- 2013